Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2014

01-11-2014 | Review

Polyamines metabolism and breast cancer: state of the art and perspectives

Authors: Manuela Cervelli, Stefano Pietropaoli, Fabrizio Signore, Roberto Amendola, Paolo Mariottini

Published in: Breast Cancer Research and Treatment | Issue 2/2014

Login to get access

Abstract

Breast cancer (BC) is a common disease that generally occurs in women over the age of 50, and the risk is especially high for women over 60 years of age. One of the major BC therapeutic problems is that tumors initially responsive to chemotherapeutic approaches can progress to more aggressive forms poorly responsive to therapies. Polyamines (PAs) are small polycationic alkylamines, naturally occurring and essential for normal cell growth and development in eukaryotes. The intracellular concentration of PA is maintained within strongly controlled contents, while a dysregulation occurs in BC cells. Polyamines facilitate the interactions of transcription factors, such as estrogen receptors with their specific response element, and are involved in the proliferation of ER-negative and highly invasive BC tumor cells. Since PA metabolism has a critical role in cell death and proliferation, it represents a potential target for intervention in BC. The goal of this study was to perform a literature search reviewing the association between PA metabolism and BC, and the current evidence supporting the BC treatment targeting PA metabolism. We here describe in vitro and in vivo models, as well as the clinical trials that have been utilized to unveil the relationship between PA metabolism and BC. Polyamine pathway is still an important target for the development of BC chemotherapy via enzyme inhibitors. Furthermore, a recent promising strategy in breast anticancer therapy is to exploit the self-regulatory nature of PA metabolism using PA analogs to affect PA homeostasis. Nowadays, antineoplastic compounds targeting the PA pathway with novel mechanisms are of great interest and high social impact for BC chemotherapy.
Literature
1.
go back to reference Rea G, Bocedi A, Cervelli M (2004) Question: what is the biological function of the polyamines? IUBMB Life 56:167–169PubMed Rea G, Bocedi A, Cervelli M (2004) Question: what is the biological function of the polyamines? IUBMB Life 56:167–169PubMed
2.
go back to reference Amendola R, Cervelli M, Fratini E, Polticelli F, Sallustio DE, Mariottini P (2009) Spermine metabolism and anticancer therapy. Curr Cancer Drug Targets 9:118–130PubMed Amendola R, Cervelli M, Fratini E, Polticelli F, Sallustio DE, Mariottini P (2009) Spermine metabolism and anticancer therapy. Curr Cancer Drug Targets 9:118–130PubMed
3.
go back to reference Nowotarski SL, Woster PM, Casero RA Jr (2013) Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med 15:e3PubMedCentralPubMed Nowotarski SL, Woster PM, Casero RA Jr (2013) Polyamines and cancer: implications for chemotherapy and chemoprevention. Expert Rev Mol Med 15:e3PubMedCentralPubMed
4.
go back to reference Russell D, Snyder SH (1968) Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci USA 60:1420–1427PubMedCentralPubMed Russell D, Snyder SH (1968) Amine synthesis in rapidly growing tissues: ornithine decarboxylase activity in regenerating rat liver, chick embryo, and various tumors. Proc Natl Acad Sci USA 60:1420–1427PubMedCentralPubMed
5.
go back to reference Thomas T, Thomas TJ (2003) Polyamine metabolism and cancer. J Cell Mol Med 7:113–126PubMed Thomas T, Thomas TJ (2003) Polyamine metabolism and cancer. J Cell Mol Med 7:113–126PubMed
6.
go back to reference Wallace HM, Duthie J, Evans DM, Lamond S, Nicoll KM, Heys SD (2000) Alterations in polyamine catabolic enzymes in human breast cancer tissue. Clin Cancer Res 6:3657–3661PubMed Wallace HM, Duthie J, Evans DM, Lamond S, Nicoll KM, Heys SD (2000) Alterations in polyamine catabolic enzymes in human breast cancer tissue. Clin Cancer Res 6:3657–3661PubMed
7.
go back to reference Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4:781–792PubMed Gerner EW, Meyskens FL Jr (2004) Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4:781–792PubMed
8.
go back to reference Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6:373–390PubMed Casero RA Jr, Marton LJ (2007) Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6:373–390PubMed
9.
go back to reference Cervelli M, Angelucci E, Germani F, Amendola R, Mariottini P (2014) Inflammation, carcinogenesis and neurodegeneration studies in transgenic animal models for polyamine research. Amino Acids 46:521–530PubMed Cervelli M, Angelucci E, Germani F, Amendola R, Mariottini P (2014) Inflammation, carcinogenesis and neurodegeneration studies in transgenic animal models for polyamine research. Amino Acids 46:521–530PubMed
11.
go back to reference Cervelli M, Amendola R, Polticelli F, Mariottini P (2012) Spermine oxidase: ten years after. Amino Acids 42:441–450PubMed Cervelli M, Amendola R, Polticelli F, Mariottini P (2012) Spermine oxidase: ten years after. Amino Acids 42:441–450PubMed
12.
go back to reference Capone C, Cervelli M, Angelucci E, Colasanti M, Macone A, Mariottini P, Persichini T (2013) A role for spermine oxidase as a mediator of reactive oxygen species production in HIV-Tat-induced neuronal toxicity. Free Radic Biol Med 63:99–107PubMed Capone C, Cervelli M, Angelucci E, Colasanti M, Macone A, Mariottini P, Persichini T (2013) A role for spermine oxidase as a mediator of reactive oxygen species production in HIV-Tat-induced neuronal toxicity. Free Radic Biol Med 63:99–107PubMed
13.
go back to reference Cervelli M, Bellavia G, D’Amelio M, Cavallucci V, Moreno S, Berger J, Nardacci R, Marcoli M, Maura G, Piacentini M, Amendola R, Cecconi F, Mariottini P (2013) A new transgenic mouse model for studying the neurotoxicity of spermine oxidase dosage in the response to excitotoxic injury. PLoS One 8:e64810PubMedCentralPubMed Cervelli M, Bellavia G, D’Amelio M, Cavallucci V, Moreno S, Berger J, Nardacci R, Marcoli M, Maura G, Piacentini M, Amendola R, Cecconi F, Mariottini P (2013) A new transgenic mouse model for studying the neurotoxicity of spermine oxidase dosage in the response to excitotoxic injury. PLoS One 8:e64810PubMedCentralPubMed
14.
go back to reference Cervelli M, Angelucci E, Stano P, Leboffe L, Federico R, Antonini G, Mariottini P, Polticelli F (2014) The Glu216–Ser218 pocket is a major determinant of spermine oxidase substrate specificity. Biochem J 463:453–459 Cervelli M, Angelucci E, Stano P, Leboffe L, Federico R, Antonini G, Mariottini P, Polticelli F (2014) The Glu216–Ser218 pocket is a major determinant of spermine oxidase substrate specificity. Biochem J 463:453–459
15.
go back to reference Manni A, Badger B, Luk G, Wright C, Caplan R, Rockette H, Bartholomew M, Ahmed SR (1988) Role of polyamines in the growth of hormone-responsive experimental breast cancer In vivo. Breast Cancer Res Treat 11:231–240PubMed Manni A, Badger B, Luk G, Wright C, Caplan R, Rockette H, Bartholomew M, Ahmed SR (1988) Role of polyamines in the growth of hormone-responsive experimental breast cancer In vivo. Breast Cancer Res Treat 11:231–240PubMed
16.
go back to reference Manni A, Badger B, Lynch J, Demers L (1990) Selectivity of polyamine involvement in hormone action on normal and neoplastic target tissues of the rat. Breast Cancer Res Treat 17:187–196 Manni A, Badger B, Lynch J, Demers L (1990) Selectivity of polyamine involvement in hormone action on normal and neoplastic target tissues of the rat. Breast Cancer Res Treat 17:187–196
17.
go back to reference Glikman P, Manni A, Demers L, Bartholomew M (1989) Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture. Cancer Res 49:1371–1376PubMed Glikman P, Manni A, Demers L, Bartholomew M (1989) Polyamine involvement in the growth of hormone-responsive and -resistant human breast cancer cells in culture. Cancer Res 49:1371–1376PubMed
18.
go back to reference Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059–2069PubMed Simpson JF, Gray R, Dressler LG, Cobau CD, Falkson CI, Gilchrist KW, Pandya KJ, Page DL, Robert NJ (2000) Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol 18:2059–2069PubMed
19.
go back to reference Manni A, Grove R, Kunselman S, Aldaz CM (1995) Involvement of the polyamine pathway in breast cancer progression. Cancer Lett 92:49–57PubMed Manni A, Grove R, Kunselman S, Aldaz CM (1995) Involvement of the polyamine pathway in breast cancer progression. Cancer Lett 92:49–57PubMed
20.
go back to reference Glikman PL, Manni A, Bartholomew M, Demers L (1990) Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture. J Steroid Biochem Mol Biol 37:1–10PubMed Glikman PL, Manni A, Bartholomew M, Demers L (1990) Polyamine involvement in basal and estradiol-stimulated insulin-like growth factor I secretion and action in breast cancer cells in culture. J Steroid Biochem Mol Biol 37:1–10PubMed
21.
go back to reference Thomas T, Thomas TJ (1994) Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res Treat 29:189–201PubMed Thomas T, Thomas TJ (1994) Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications. Breast Cancer Res Treat 29:189–201PubMed
22.
go back to reference Shah N, Thomas T, Shirahata A, Sigal LH, Thomas TJ (1999) Activation of nuclear factor kappaB by polyamines in breast cancer cells. Biochemistry 38:14763–14774PubMed Shah N, Thomas T, Shirahata A, Sigal LH, Thomas TJ (1999) Activation of nuclear factor kappaB by polyamines in breast cancer cells. Biochemistry 38:14763–14774PubMed
23.
go back to reference Balabhadrapathruni S, Santhakumaran LM, Thomas TJ, Shirahata A, Gallo MA, Thomas T (2005) Bis(ethyl)norspermine potentiates the apoptotic activity of the pure antiestrogen ICI 182780 in breast cancer cells. Oncol Rep 13:101–108PubMed Balabhadrapathruni S, Santhakumaran LM, Thomas TJ, Shirahata A, Gallo MA, Thomas T (2005) Bis(ethyl)norspermine potentiates the apoptotic activity of the pure antiestrogen ICI 182780 in breast cancer cells. Oncol Rep 13:101–108PubMed
24.
go back to reference Faaland CA, Thomas TJ, Balabhadrapathruni S, Langer T, Mian S, Shirahata A, Gallo MA, Thomas T (2000) Molecular correlates of the action of bis(ethyl)polyamines in breast cancer cell growth inhibition and apoptosis. Biochem Cell Biol 78:415–426PubMed Faaland CA, Thomas TJ, Balabhadrapathruni S, Langer T, Mian S, Shirahata A, Gallo MA, Thomas T (2000) Molecular correlates of the action of bis(ethyl)polyamines in breast cancer cell growth inhibition and apoptosis. Biochem Cell Biol 78:415–426PubMed
25.
go back to reference Cervelli M, Bellavia G, Fratini E, Amendola R, Polticelli F, Barba M, Federico R, Signore F, Gucciardo G, Grillo R, Woster PM, Casero RA Jr, Mariottini P (2010) Spermine oxidase (SMO) activity in breast tumor tissues and biochemical analysis of the anticancer spermine analogues BENSpm and CPENSpm. BMC Cancer 10:555PubMedCentralPubMed Cervelli M, Bellavia G, Fratini E, Amendola R, Polticelli F, Barba M, Federico R, Signore F, Gucciardo G, Grillo R, Woster PM, Casero RA Jr, Mariottini P (2010) Spermine oxidase (SMO) activity in breast tumor tissues and biochemical analysis of the anticancer spermine analogues BENSpm and CPENSpm. BMC Cancer 10:555PubMedCentralPubMed
26.
go back to reference Seiler N (2003) Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 4:537–564PubMed Seiler N (2003) Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 4:537–564PubMed
27.
go back to reference Amendola R, Cervelli M, Fratini E, Sallustio DE, Tempera G, Ueshima T, Mariottini P, Agostinelli E (2014) Reactive oxygen species spermine metabolites generated from amine oxidases and radiation represent a therapeutic gain in cancer treatments. Int J Oncol 43:813–820 Amendola R, Cervelli M, Fratini E, Sallustio DE, Tempera G, Ueshima T, Mariottini P, Agostinelli E (2014) Reactive oxygen species spermine metabolites generated from amine oxidases and radiation represent a therapeutic gain in cancer treatments. Int J Oncol 43:813–820
28.
go back to reference Amendola R, Cervelli M, Tempera G, Fratini E, Varesio L, Mariottini P, Agostinelli E (2014) Spermine metabolism and radiation-derived reactive oxygen species for future therapeutic implications in cancer: an additive or adaptive response. Amino Acids 46:487–498PubMed Amendola R, Cervelli M, Tempera G, Fratini E, Varesio L, Mariottini P, Agostinelli E (2014) Spermine metabolism and radiation-derived reactive oxygen species for future therapeutic implications in cancer: an additive or adaptive response. Amino Acids 46:487–498PubMed
29.
go back to reference Schipper RG, Penning LC, Verhofstad AA (2000) Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Semin Cancer Biol 10:55–68PubMed Schipper RG, Penning LC, Verhofstad AA (2000) Involvement of polyamines in apoptosis. Facts and controversies: effectors or protectors? Semin Cancer Biol 10:55–68PubMed
30.
go back to reference Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2:244–258 Thomas T, Thomas TJ (2001) Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2:244–258
32.
go back to reference Feuerstein BG, Williams LD, Basu HS, Marton LJ (1991) Implications and concepts of polyamine–nucleic acid interactions. J Cell Biochem 46:37–47PubMed Feuerstein BG, Williams LD, Basu HS, Marton LJ (1991) Implications and concepts of polyamine–nucleic acid interactions. J Cell Biochem 46:37–47PubMed
33.
go back to reference Matthews HR (1993) Polyamines, chromatin structure and transcription. BioEssays 15:561–566PubMed Matthews HR (1993) Polyamines, chromatin structure and transcription. BioEssays 15:561–566PubMed
35.
go back to reference Wallace HM (2000) The physiological role of the polyamines. Eur J Clin Invest 30:1–3PubMed Wallace HM (2000) The physiological role of the polyamines. Eur J Clin Invest 30:1–3PubMed
36.
go back to reference Upp JR Jr, Saydjari R, Townsend CM Jr, Singh P, Barranco SC, Thompson JC (1988) Polyamine levels and gastrin receptors in colon cancers. Ann Surg 207:662–669PubMedCentralPubMed Upp JR Jr, Saydjari R, Townsend CM Jr, Singh P, Barranco SC, Thompson JC (1988) Polyamine levels and gastrin receptors in colon cancers. Ann Surg 207:662–669PubMedCentralPubMed
37.
go back to reference Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H (2000) Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60:5125–5133PubMed Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H (2000) Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60:5125–5133PubMed
39.
go back to reference Manni A, Astrow SH, Gammon S, Thompson J, Mauger D, Washington S (2001) Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 67:147–156PubMed Manni A, Astrow SH, Gammon S, Thompson J, Mauger D, Washington S (2001) Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 67:147–156PubMed
40.
go back to reference Deng W, Jiang X, Mei Y, Sun J, Ma R, Liu X, Sun H, Tian H, Sun X (2008) Role of ornithine decarboxylase in breast cancer. Acta Biochim Biophys 40:235–243 Deng W, Jiang X, Mei Y, Sun J, Ma R, Liu X, Sun H, Tian H, Sun X (2008) Role of ornithine decarboxylase in breast cancer. Acta Biochim Biophys 40:235–243
41.
go back to reference Manni A, Mauger D, Gimotty P, Badger B (1996) Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res 2:1901–1906PubMed Manni A, Mauger D, Gimotty P, Badger B (1996) Prognostic influence on survival of increased ornithine decarboxylase activity in human breast cancer. Clin Cancer Res 2:1901–1906PubMed
42.
go back to reference Glikman P, Vegh I, Pollina MA, Mosto AH, Levy CM (1987) Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer 60:2237–2243PubMed Glikman P, Vegh I, Pollina MA, Mosto AH, Levy CM (1987) Ornithine decarboxylase activity, prolactin blood levels, and estradiol and progesterone receptors in human breast cancer. Cancer 60:2237–2243PubMed
43.
go back to reference Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G (1989) Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165–1171PubMed Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G, Mezzanotte G, Bonadonna G (1989) Cell kinetics as a prognostic indicator in node-negative breast cancer. Eur J Cancer Clin Oncol 25:1165–1171PubMed
44.
go back to reference Perez G, Olivares IM, Rodriguez MG, Ceballos GM, Garcia Sanchez JR (2012) Arginase activity in patients with breast cancer: an analysis of plasma, tumors, and its relationship with the presence of the estrogen receptor. Onkologie 35:570–574PubMed Perez G, Olivares IM, Rodriguez MG, Ceballos GM, Garcia Sanchez JR (2012) Arginase activity in patients with breast cancer: an analysis of plasma, tumors, and its relationship with the presence of the estrogen receptor. Onkologie 35:570–574PubMed
45.
go back to reference Pledgie A, Huang Y, Hacker A, Zhang Z, Woster PM, Davidson E, Casero RA Jr (2005) Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. J Biol Chem 280:39843–39851PubMed Pledgie A, Huang Y, Hacker A, Zhang Z, Woster PM, Davidson E, Casero RA Jr (2005) Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. J Biol Chem 280:39843–39851PubMed
46.
go back to reference Casero RA Jr, Pegg AE (1993) Spermidine/spermine N 1-acetyltransferase—the turning point in polyamine metabolism. FASEB J 7:653–661PubMed Casero RA Jr, Pegg AE (1993) Spermidine/spermine N 1-acetyltransferase—the turning point in polyamine metabolism. FASEB J 7:653–661PubMed
47.
go back to reference Tavladoraki P, Cervelli M, Antonangeli F, Minervini G, Stano P, Federico R, Mariottini P, Polticelli F (2011) Probing mammalian spermine oxidase enzyme-substrate complex through molecular modeling, site-directed mutagenesis and biochemical characterization. Amino Acids 40:1115–1126PubMed Tavladoraki P, Cervelli M, Antonangeli F, Minervini G, Stano P, Federico R, Mariottini P, Polticelli F (2011) Probing mammalian spermine oxidase enzyme-substrate complex through molecular modeling, site-directed mutagenesis and biochemical characterization. Amino Acids 40:1115–1126PubMed
48.
go back to reference Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW (2003) Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine backconversion. Biochem J 370(Pt 1):19–28PubMedCentralPubMed Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW (2003) Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine backconversion. Biochem J 370(Pt 1):19–28PubMedCentralPubMed
49.
go back to reference Polticelli F, Salvi D, Mariottini P, Amendola R, Cervelli M (2012) Molecular evolution of the polyamine oxidase gene family in Metazoa. BMC Evol Biol 12:90PubMedCentralPubMed Polticelli F, Salvi D, Mariottini P, Amendola R, Cervelli M (2012) Molecular evolution of the polyamine oxidase gene family in Metazoa. BMC Evol Biol 12:90PubMedCentralPubMed
50.
go back to reference Cervelli M, Salvi D, Polticelli F, Amendola R, Mariottini P (2013) Structure–function relationships in the evolutionary framework of spermine oxidase. J Mol Evol 76:365–370PubMed Cervelli M, Salvi D, Polticelli F, Amendola R, Mariottini P (2013) Structure–function relationships in the evolutionary framework of spermine oxidase. J Mol Evol 76:365–370PubMed
51.
go back to reference Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW (2002) Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 367(Pt 3):665–675PubMedCentralPubMed Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW (2002) Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 367(Pt 3):665–675PubMedCentralPubMed
52.
go back to reference Cervelli M, Polticelli F, Federico F, Mariottini P (2003) Heterologous expression and characterization of mouse spermine oxidase. J Biol Chem 278:5271–5276PubMed Cervelli M, Polticelli F, Federico F, Mariottini P (2003) Heterologous expression and characterization of mouse spermine oxidase. J Biol Chem 278:5271–5276PubMed
53.
go back to reference Cervelli M, Bellini A, Bianchi M, Marcocci L, Nocera S, Polticelli F, Federico R, Amendola R, Mariottini P (2004) Mouse spermine oxidase gene splice variants. Nuclear subcellular localization of a novel active isoform. Eur J Biochem 271:760–770PubMed Cervelli M, Bellini A, Bianchi M, Marcocci L, Nocera S, Polticelli F, Federico R, Amendola R, Mariottini P (2004) Mouse spermine oxidase gene splice variants. Nuclear subcellular localization of a novel active isoform. Eur J Biochem 271:760–770PubMed
55.
go back to reference Babbar N, Casero RA Jr (2006) Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 66:11125–11130PubMed Babbar N, Casero RA Jr (2006) Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 66:11125–11130PubMed
56.
go back to reference Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, Casero RA Jr (2011) Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis induced colon tumorigenesis. Proc Natl Acad Sci USA 108:15354–15359PubMedCentralPubMed Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, Casero RA Jr (2011) Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis induced colon tumorigenesis. Proc Natl Acad Sci USA 108:15354–15359PubMedCentralPubMed
57.
go back to reference Bana E, Bagrel D (2011) In vitro breast cancer models as useful tools in therapeutics? In: Gunduz M, Gunduz E (eds), Breast cancer focusing tumor microenvironment, stem cells and metastasis, chapter 2. Publisher InTech, pp 21–38 Bana E, Bagrel D (2011) In vitro breast cancer models as useful tools in therapeutics? In: Gunduz M, Gunduz E (eds), Breast cancer focusing tumor microenvironment, stem cells and metastasis, chapter 2. Publisher InTech, pp 21–38
58.
59.
go back to reference Lacroix M (2008) Persistent use of “false” cell lines. Int J Cancer 122:1–4PubMed Lacroix M (2008) Persistent use of “false” cell lines. Int J Cancer 122:1–4PubMed
60.
go back to reference Cohen FJ, Manni A, Glikman P, Bartholomew M, Demers L (1988) Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. Cancer Res 48:6819–6825PubMed Cohen FJ, Manni A, Glikman P, Bartholomew M, Demers L (1988) Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. Cancer Res 48:6819–6825PubMed
61.
go back to reference Kim I, Manni A, Lynch J, Demers L (1991) Polyamine involvement in the secretion and action of TGF-alpha in hormone sensitive human breast cancer cells in culture. Breast Cancer Res Treat 18:83–91PubMed Kim I, Manni A, Lynch J, Demers L (1991) Polyamine involvement in the secretion and action of TGF-alpha in hormone sensitive human breast cancer cells in culture. Breast Cancer Res Treat 18:83–91PubMed
62.
go back to reference Manni A, Badger B, Grove R, Kunselman S, Demers L (1995) Isolation and characterization of human breast cancer cells overexpressing S-adenosylmethionine decarboxylase. Cancer Lett 95:23–28PubMed Manni A, Badger B, Grove R, Kunselman S, Demers L (1995) Isolation and characterization of human breast cancer cells overexpressing S-adenosylmethionine decarboxylase. Cancer Lett 95:23–28PubMed
63.
go back to reference Manni A, Badger B, Wechter R, Kunselman S, Rossini A, Demers L (1995) Biochemical and growth-modulatory effects of the new S-adenosylmethionine decarboxylase inhibitor CGP 48664 in malignant and immortalized normal human breast epithelial cells in culture. Int J Cancer 62:485–491PubMed Manni A, Badger B, Wechter R, Kunselman S, Rossini A, Demers L (1995) Biochemical and growth-modulatory effects of the new S-adenosylmethionine decarboxylase inhibitor CGP 48664 in malignant and immortalized normal human breast epithelial cells in culture. Int J Cancer 62:485–491PubMed
64.
go back to reference Thomas T, Faaland CA, Adhikarakunnathu S, Thomas TJ (1996) Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Breast Cancer Res Treat 139:293–306 Thomas T, Faaland CA, Adhikarakunnathu S, Thomas TJ (1996) Structure-activity relations of S-adenosylmethionine decarboxylase inhibitors on the growth of MCF-7 breast cancer cells. Breast Cancer Res Treat 139:293–306
65.
go back to reference Manni A, Wechter R, Grove R, Wei L, Martel J, Demers L (1995) Polyamine profiles and growth properties of ornithine decarboxylase overexpressing MCF-7 breast cancer cells in culture. Breast Cancer Res Treat 34:45–53PubMed Manni A, Wechter R, Grove R, Wei L, Martel J, Demers L (1995) Polyamine profiles and growth properties of ornithine decarboxylase overexpressing MCF-7 breast cancer cells in culture. Breast Cancer Res Treat 34:45–53PubMed
66.
go back to reference Manni A, Wechter R, Gilmour S, Verderame MF, Mauger D, Demers LM (1997) Ornithine decarboxylase over-expression stimulates mitogen-activated protein kinase and anchorage-independent growth of human breast epithelial cells. Int J Cancer 70:175–182PubMed Manni A, Wechter R, Gilmour S, Verderame MF, Mauger D, Demers LM (1997) Ornithine decarboxylase over-expression stimulates mitogen-activated protein kinase and anchorage-independent growth of human breast epithelial cells. Int J Cancer 70:175–182PubMed
67.
go back to reference Zaletok S, Alexandrova N, Berdynskykh N, Ignatenko N, Gogol S, Orlovsky O, Tregubova N, Gerner E, Chekhun V (2004) Role of polyamines in the function of nuclear transcription factor NF-κB in breast cancer cells. Exp Oncol 26:221–225PubMed Zaletok S, Alexandrova N, Berdynskykh N, Ignatenko N, Gogol S, Orlovsky O, Tregubova N, Gerner E, Chekhun V (2004) Role of polyamines in the function of nuclear transcription factor NF-κB in breast cancer cells. Exp Oncol 26:221–225PubMed
68.
go back to reference Pavlov V, Rodilla V, Kong Thoo Lin P (2002) Growth, morphological and biochemical changes in oxa-spermine derivative-treated MCF-7 human breast cancer cells. Life Sci 71:1161–1173PubMed Pavlov V, Rodilla V, Kong Thoo Lin P (2002) Growth, morphological and biochemical changes in oxa-spermine derivative-treated MCF-7 human breast cancer cells. Life Sci 71:1161–1173PubMed
69.
go back to reference Pavlov V, Lin PK, Rodilla V (2002) Biochemical effects and growth inhibition in MCF-7 cells caused by novel sulphonamido oxa-polyamine derivatives. Cell Mol Life Sci 59:715–723PubMed Pavlov V, Lin PK, Rodilla V (2002) Biochemical effects and growth inhibition in MCF-7 cells caused by novel sulphonamido oxa-polyamine derivatives. Cell Mol Life Sci 59:715–723PubMed
70.
go back to reference Zhu Q, Jin L, Casero RA Jr, Davidson NE, Huang Y (2012) Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. Breast Cancer Res Treat 136:57–66PubMedCentralPubMed Zhu Q, Jin L, Casero RA Jr, Davidson NE, Huang Y (2012) Role of ornithine decarboxylase in regulation of estrogen receptor alpha expression and growth in human breast cancer cells. Breast Cancer Res Treat 136:57–66PubMedCentralPubMed
71.
go back to reference Arisan ED, Obakan P, Coker A, Palavan-Unsal N (2012) Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells. Mol Med Rep 5:1323–1329PubMed Arisan ED, Obakan P, Coker A, Palavan-Unsal N (2012) Inhibition of ornithine decarboxylase alters the roscovitine-induced mitochondrial-mediated apoptosis in MCF-7 breast cancer cells. Mol Med Rep 5:1323–1329PubMed
72.
go back to reference Obakan P, Arısan ED, Özfiliz P, Çoker-Gürkan A, Palavan-Ünsal N (2014) Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells. Mol Biol Rep 41:145–154PubMed Obakan P, Arısan ED, Özfiliz P, Çoker-Gürkan A, Palavan-Ünsal N (2014) Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells. Mol Biol Rep 41:145–154PubMed
73.
go back to reference Bey P, Bolkenius FN, Seiler N, Casara P (1985) N-2,3-butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem 28:1–2PubMed Bey P, Bolkenius FN, Seiler N, Casara P (1985) N-2,3-butadienyl-1,4-butanediamine derivatives: potent irreversible inactivators of mammalian polyamine oxidase. J Med Chem 28:1–2PubMed
74.
go back to reference Bellelli A, Cavallo S, Nicolini L, Cervelli M, Bianchi M, Mariottini P, Zelli M, Federico R (2004) Mouse spermine oxidase: a model of the catalytic cycle and its inhibition by N, N 1-bis(2,3-butadienyl)-1,4-butanediamine. Biochem Biophys Res Commun. 322:1–8PubMed Bellelli A, Cavallo S, Nicolini L, Cervelli M, Bianchi M, Mariottini P, Zelli M, Federico R (2004) Mouse spermine oxidase: a model of the catalytic cycle and its inhibition by N, N 1-bis(2,3-butadienyl)-1,4-butanediamine. Biochem Biophys Res Commun. 322:1–8PubMed
75.
go back to reference Bianchi M, Bellini A, Cervelli M, Degan P, Marcocci L, Martini F, Scatteia M, Mariottini P, Amendola R (2007) Chronic sub-lethal oxidative stress by spermine oxidase overactivity induces continuous DNA repair and hypersensitivity to radiation exposure. Biochim Biophys Acta 1773:774–783PubMed Bianchi M, Bellini A, Cervelli M, Degan P, Marcocci L, Martini F, Scatteia M, Mariottini P, Amendola R (2007) Chronic sub-lethal oxidative stress by spermine oxidase overactivity induces continuous DNA repair and hypersensitivity to radiation exposure. Biochim Biophys Acta 1773:774–783PubMed
76.
go back to reference Holst CM, Johansson VM, Alm K, Oredsson SM (2008) Novel anti-apoptotic effect of Bcl-2: prevention of polyamine depletion-induced cell death. Cell Biol Int 32:66–74PubMed Holst CM, Johansson VM, Alm K, Oredsson SM (2008) Novel anti-apoptotic effect of Bcl-2: prevention of polyamine depletion-induced cell death. Cell Biol Int 32:66–74PubMed
77.
go back to reference Nair SK, Verma A, Thomas TJ, Chou TC, Gallo MA, Shirahata A, Thomas T (2007) Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Lett 250:311–322PubMedCentralPubMed Nair SK, Verma A, Thomas TJ, Chou TC, Gallo MA, Shirahata A, Thomas T (2007) Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Lett 250:311–322PubMedCentralPubMed
78.
go back to reference Pledgie-Tracey A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA Jr, Davidson NE (2010) The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic eVects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother Pharmacol 65:1067–1081 Pledgie-Tracey A, Billam M, Hacker A, Sobolewski MD, Woster PM, Zhang Z, Casero RA Jr, Davidson NE (2010) The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic eVects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother Pharmacol 65:1067–1081
79.
go back to reference Saab MH, West EE, Bieszk NC, Preuss C, Mank AR, Casero RA Jr, Woster PM (1993) Synthesis and evaluation of unsymmetrically substituted polyamine analogues as modulators of human spermidine/spermine-N1-acetyltransferase (SSAT) and as potential anti-tumor agents. J Med Chem 36:2998–3004PubMed Saab MH, West EE, Bieszk NC, Preuss C, Mank AR, Casero RA Jr, Woster PM (1993) Synthesis and evaluation of unsymmetrically substituted polyamine analogues as modulators of human spermidine/spermine-N1-acetyltransferase (SSAT) and as potential anti-tumor agents. J Med Chem 36:2998–3004PubMed
80.
go back to reference Casero RA Jr, Mank AR, Saab NH, Wu R, Dyer WJ, Woster PM (1995) Growth and biochemical effects of unsymmetrically substituted polyamine analogues in human lung tumor cells 1. Cancer Chemother Pharmacol 36:69–74PubMed Casero RA Jr, Mank AR, Saab NH, Wu R, Dyer WJ, Woster PM (1995) Growth and biochemical effects of unsymmetrically substituted polyamine analogues in human lung tumor cells 1. Cancer Chemother Pharmacol 36:69–74PubMed
81.
go back to reference McCloskey DE, Casero RA Jr, Woster PM, Davidson NE (1995) Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res 55:3233–3236PubMed McCloskey DE, Casero RA Jr, Woster PM, Davidson NE (1995) Induction of programmed cell death in human breast cancer cells by an unsymmetrically alkylated polyamine analogue. Cancer Res 55:3233–3236PubMed
82.
go back to reference Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA Jr (1999) Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer 6:69–73PubMed Davidson NE, Hahm HA, McCloskey DE, Woster PM, Casero RA Jr (1999) Clinical aspects of cell death in breast cancer: the polyamine pathway as a new target for treatment. Endocr Relat Cancer 6:69–73PubMed
83.
go back to reference Varghese S, Gupta D, Baran T, Jiemjit A, Gore SD, Casero RA Jr, Woster PM (2005) Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors. J Med Chem 48:6350–6365PubMedCentralPubMed Varghese S, Gupta D, Baran T, Jiemjit A, Gore SD, Casero RA Jr, Woster PM (2005) Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors. J Med Chem 48:6350–6365PubMedCentralPubMed
84.
go back to reference Varghese S, Senanayake T, Murray-Stewart T, Doering K, Fraser A, Casero RA Jr, Woster PM (2008) Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. J Med Chem 51:2447–2456PubMedCentralPubMed Varghese S, Senanayake T, Murray-Stewart T, Doering K, Fraser A, Casero RA Jr, Woster PM (2008) Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors. J Med Chem 51:2447–2456PubMedCentralPubMed
85.
go back to reference Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr (2007) Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 104:8023–8028PubMedCentralPubMed Huang Y, Greene E, Murray Stewart T, Goodwin AC, Baylin SB, Woster PM, Casero RA Jr (2007) Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc Natl Acad Sci USA 104:8023–8028PubMedCentralPubMed
86.
go back to reference Wu Y, Steinbergs N, Murray-Stewart T, Marton LJ, Casero RA Jr (2012) Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. Biochem J 442:693–701PubMedCentralPubMed Wu Y, Steinbergs N, Murray-Stewart T, Marton LJ, Casero RA Jr (2012) Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. Biochem J 442:693–701PubMedCentralPubMed
87.
go back to reference Hahm HA, Dunn VR, Butash KA, Deveraux WL, Woster PM, Casero RA Jr, Davidson NE (2001) Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res 7:391–399PubMed Hahm HA, Dunn VR, Butash KA, Deveraux WL, Woster PM, Casero RA Jr, Davidson NE (2001) Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines. Clin Cancer Res 7:391–399PubMed
88.
go back to reference Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA Jr, Marton LJ, Cleveland JL (2008) The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res 68:4783–4790PubMedCentralPubMed Carew JS, Nawrocki ST, Reddy VK, Bush D, Rehg JE, Goodwin A, Houghton JA, Casero RA Jr, Marton LJ, Cleveland JL (2008) The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Res 68:4783–4790PubMedCentralPubMed
89.
go back to reference Hacker A, Marton LJ, Sobolewski M, Casero RA Jr (2008) In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 63:45–53PubMedCentralPubMed Hacker A, Marton LJ, Sobolewski M, Casero RA Jr (2008) In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells. Cancer Chemother Pharmacol 63:45–53PubMedCentralPubMed
90.
go back to reference Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM (2010) Reduction of the putative CD44 + CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Anticancer Drugs 21:897–906PubMed Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM (2010) Reduction of the putative CD44 + CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047. Anticancer Drugs 21:897–906PubMed
91.
go back to reference Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr (2012) Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 42:887–898PubMedCentralPubMed Zhu Q, Huang Y, Marton LJ, Woster PM, Davidson NE, Casero RA Jr (2012) Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 42:887–898PubMedCentralPubMed
92.
go back to reference Silva TM, Fiuza SM, Marques MPM, Persson L, Oredsson S (2014) Increased breast cancer cell toxicity by palladination of the polyamine analogue N1, N11-bis(ethyl)norspermine. Amino Acids 46:339–352PubMedCentralPubMed Silva TM, Fiuza SM, Marques MPM, Persson L, Oredsson S (2014) Increased breast cancer cell toxicity by palladination of the polyamine analogue N1, N11-bis(ethyl)norspermine. Amino Acids 46:339–352PubMedCentralPubMed
93.
go back to reference Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131–146PubMed Brabec V, Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131–146PubMed
94.
go back to reference Esteban-Fernández D, Moreno-Gordaliza E, Cañas B, Palacios MA, Gómez-Gómez MM (2010) Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. Metallomics 2:19–38PubMed Esteban-Fernández D, Moreno-Gordaliza E, Cañas B, Palacios MA, Gómez-Gómez MM (2010) Analytical methodologies for metallomics studies of antitumor Pt-containing drugs. Metallomics 2:19–38PubMed
95.
go back to reference Silva TM, Andersson S, Sukumaran SK, Marques MP, Persson L, Oredsson S (2013) Norspermidine and novel Pd(II) and Pt(II) polynuclear complexes of norspermidine as potential antineoplastic agents against breast cancer. PLoS ONE 8(2):e55651PubMedCentralPubMed Silva TM, Andersson S, Sukumaran SK, Marques MP, Persson L, Oredsson S (2013) Norspermidine and novel Pd(II) and Pt(II) polynuclear complexes of norspermidine as potential antineoplastic agents against breast cancer. PLoS ONE 8(2):e55651PubMedCentralPubMed
96.
go back to reference Silva TM, Oredsson S, Persson L, Woster P, Marques MP (2012) Novel Pt(II) and Pd(II) complexes with polyamine analogues: synthesis and vibrational analysis. J Inorg Biochem 108:1–7PubMed Silva TM, Oredsson S, Persson L, Woster P, Marques MP (2012) Novel Pt(II) and Pd(II) complexes with polyamine analogues: synthesis and vibrational analysis. J Inorg Biochem 108:1–7PubMed
97.
go back to reference Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A (2008) Effects of polyamine depletion by α-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 107:33–40PubMed Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A (2008) Effects of polyamine depletion by α-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 107:33–40PubMed
98.
go back to reference Shah N, Antony T, Haddad S, Amenta P, Shirahata A, Thomas TJ, Thomas T (1999) Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice. Cancer Lett 146:15–23PubMed Shah N, Antony T, Haddad S, Amenta P, Shirahata A, Thomas TJ, Thomas T (1999) Antitumor effects of bis(ethyl)polyamine analogs on mammary tumor development in FVB/NTgN (MMTVneu) transgenic mice. Cancer Lett 146:15–23PubMed
99.
go back to reference Manni A, Badger B, Martel J, Demers L (1992) Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice. Cancer Lett 66:1–9PubMed Manni A, Badger B, Martel J, Demers L (1992) Role of polyamines in the growth of hormone-responsive and -resistant human breast cancer cells in nude mice. Cancer Lett 66:1–9PubMed
100.
go back to reference Thomas T, Shah N, Faaland C, Gallo M, Yurkow E, Satyaswaroop P (1997) Effects of a bis(benzyl)spermine analog on MCF-7 breast cancer cells in culture and nude mice xenografts. Oncol Rep 4:5–13PubMed Thomas T, Shah N, Faaland C, Gallo M, Yurkow E, Satyaswaroop P (1997) Effects of a bis(benzyl)spermine analog on MCF-7 breast cancer cells in culture and nude mice xenografts. Oncol Rep 4:5–13PubMed
101.
go back to reference Leveque J, Foucher F, Havouis R, Desury D, Grall JY, Moulinoux JP (2000) Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo. Anticancer Res 20:97–101PubMed Leveque J, Foucher F, Havouis R, Desury D, Grall JY, Moulinoux JP (2000) Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo. Anticancer Res 20:97–101PubMed
102.
go back to reference Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS, Welch DR (2002) Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 19:95–105PubMed Manni A, Washington S, Griffith JW, Verderame MF, Mauger D, Demers LM, Samant RS, Welch DR (2002) Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells. Clin Exp Metastasis 19:95–105PubMed
103.
go back to reference Prakash NJ, Schechter PJ, Grove J, Koch-Weser J (1978) Effect of alphadifluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice. Cancer Res 38:3059–3062PubMed Prakash NJ, Schechter PJ, Grove J, Koch-Weser J (1978) Effect of alphadifluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on L1210 leukemia in mice. Cancer Res 38:3059–3062PubMed
104.
go back to reference Herrmann AL, Nelson FR, Slaga TJ (1982) Alphadifluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79:6028–6032PubMedCentralPubMed Herrmann AL, Nelson FR, Slaga TJ (1982) Alphadifluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79:6028–6032PubMedCentralPubMed
105.
go back to reference Mamont PS, Duchesne MC, Grove J, Bey P (1978) Anti-proliferative properties of DL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Comm 81:58–66PubMed Mamont PS, Duchesne MC, Grove J, Bey P (1978) Anti-proliferative properties of DL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Comm 81:58–66PubMed
106.
go back to reference Herr HW, Warrel RP, Burchenal JH (1986) Phase I trial of α-difluoromethylornithine (DFMO) and methylglyoxal bis(guanylhydrazone) (MGBG) in patients with advanced prostatic cancer. Urology 28:508–511PubMed Herr HW, Warrel RP, Burchenal JH (1986) Phase I trial of α-difluoromethylornithine (DFMO) and methylglyoxal bis(guanylhydrazone) (MGBG) in patients with advanced prostatic cancer. Urology 28:508–511PubMed
107.
go back to reference Meyskens FL Jr, Kingsley EM, Glattke T, Loescher L, Booth A (1986) A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4:257–262PubMed Meyskens FL Jr, Kingsley EM, Glattke T, Loescher L, Booth A (1986) A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4:257–262PubMed
108.
go back to reference Horn Y, Schechter PJ, Marton LJ (1987) Phase I-II clinical trial with α-difluoromethylornithine—an inhibitor of polyamine biosynthesis. Eur J Cancer Clin Oncol 23:1103–1107PubMed Horn Y, Schechter PJ, Marton LJ (1987) Phase I-II clinical trial with α-difluoromethylornithine—an inhibitor of polyamine biosynthesis. Eur J Cancer Clin Oncol 23:1103–1107PubMed
109.
go back to reference Ganju V, Edmonson JH, Buckner JC (1994) Phase I study of combined α interferon, -difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy. Invest New Drugs 12:25–27PubMed Ganju V, Edmonson JH, Buckner JC (1994) Phase I study of combined α interferon, -difluoromethylornithine (DFMO), and doxorubicin in advanced malignancy. Invest New Drugs 12:25–27PubMed
110.
go back to reference Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K (1998) Phase I dose de-escalation trial of -difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4:303–310PubMed Mitchell MF, Tortolero-Luna G, Lee JJ, Hittelman WN, Lotan R, Wharton JT, Hong WK, Nishioka K (1998) Phase I dose de-escalation trial of -difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res 4:303–310PubMed
111.
go back to reference O’Shaughnessy JA, Demers LM, Jones SE, Arsenau J, Khandelwal P, George T, Gersh R, Mauger D, Manni A (1999) α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 5:3438–3444PubMed O’Shaughnessy JA, Demers LM, Jones SE, Arsenau J, Khandelwal P, George T, Gersh R, Mauger D, Manni A (1999) α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 5:3438–3444PubMed
112.
go back to reference Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77PubMed Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA (2001) Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 49:71–77PubMed
113.
go back to reference Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA (2002) A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8:3105–3117PubMed Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA (2002) A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8:3105–3117PubMed
114.
go back to reference Levin VA, Hess KR, Choucair A, Flynn P, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination -difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981–990PubMed Levin VA, Hess KR, Choucair A, Flynn P, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW (2003) Phase III randomized study of postradiotherapy chemotherapy with combination -difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981–990PubMed
115.
go back to reference Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O’Brien TG (2006) Combination therapy with 2-difluoromethylornithine and a polyamone transport inhibitor against murine squamous cell carcinoma. Int J Cancer 118:2344–2349PubMed Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O’Brien TG (2006) Combination therapy with 2-difluoromethylornithine and a polyamone transport inhibitor against murine squamous cell carcinoma. Int J Cancer 118:2344–2349PubMed
116.
go back to reference Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W (1998) Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90:1212–1218PubMed Meyskens FL Jr, Gerner EW, Emerson S, Pelot D, Durbin T, Doyle K, Lagerberg W (1998) Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90:1212–1218PubMed
117.
go back to reference Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32–38 Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, Turgeon DK, Goldschmid S, Lance P, Hagedorn CH, Gillen DL, Gerner EW (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1:32–38
118.
go back to reference Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17:292–299PubMedCentralPubMed Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL Jr (2008) The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 17:292–299PubMedCentralPubMed
119.
go back to reference Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M (1992) Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84:1432–1437PubMed Levin VA, Prados MD, Yung WK, Gleason MJ, Ictech S, Malec M (1992) Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84:1432–1437PubMed
120.
go back to reference Porter CW, Bergeron RJ (1988) Regulation of polyamine biosynthetic activity by spermidine and spermine analogs, a novel antiproliferative strategy. Adv Exp Med Biol 250:677–690PubMed Porter CW, Bergeron RJ (1988) Regulation of polyamine biosynthetic activity by spermidine and spermine analogs, a novel antiproliferative strategy. Adv Exp Med Biol 250:677–690PubMed
121.
go back to reference Casero RA Jr, Woster PM (2001) Terminally alkylated polyamine analogues as chemotherapeutic agents. J Med Chem 44:1–26PubMed Casero RA Jr, Woster PM (2001) Terminally alkylated polyamine analogues as chemotherapeutic agents. J Med Chem 44:1–26PubMed
122.
go back to reference Casero RA Jr, Woster PM (2009) Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem 52:4551–4573PubMedCentralPubMed Casero RA Jr, Woster PM (2009) Recent advances in the development of polyamine analogues as antitumor agents. J Med Chem 52:4551–4573PubMedCentralPubMed
123.
go back to reference Casero RA Jr, Gabrielson EW, Pegg AE (1994) Immunohistochemical staining of human spermidine/spermine N1-acetyltransferase superinduced in response to treatment with antitumor polyamine analogues. Cancer Res 54:3955–3958PubMed Casero RA Jr, Gabrielson EW, Pegg AE (1994) Immunohistochemical staining of human spermidine/spermine N1-acetyltransferase superinduced in response to treatment with antitumor polyamine analogues. Cancer Res 54:3955–3958PubMed
124.
go back to reference Gabrielson EW, Pegg AE, Casero RA Jr (1999) The induction of spermidine/spermine N1-acetyltransferase (SSAT) is a common event in the response of human primary non-small cell lung carcinomas to exposure to the new antitumor polyamine analogue N1, N11-bis(ethyl)norspermine. Clin Cancer Res 5:1638–1641PubMed Gabrielson EW, Pegg AE, Casero RA Jr (1999) The induction of spermidine/spermine N1-acetyltransferase (SSAT) is a common event in the response of human primary non-small cell lung carcinomas to exposure to the new antitumor polyamine analogue N1, N11-bis(ethyl)norspermine. Clin Cancer Res 5:1638–1641PubMed
125.
go back to reference Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW (1995) Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. Clin Cancer Res 1:847–857PubMed Bernacki RJ, Oberman EJ, Seweryniak KE, Atwood A, Bergeron RJ, Porter CW (1995) Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. Clin Cancer Res 1:847–857PubMed
126.
go back to reference Streiff RR, Bender JF (2001) Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest New Drugs 19:29–39PubMed Streiff RR, Bender JF (2001) Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest New Drugs 19:29–39PubMed
127.
go back to reference Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero RA Jr, Davidson NE (2003) A phase II study of the polyamine analog N1, N11-diethylnorspermine (DENSPM) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res 9:5922–5928PubMed Wolff AC, Armstrong DK, Fetting JH, Carducci MK, Riley CD, Bender JF, Casero RA Jr, Davidson NE (2003) A phase II study of the polyamine analog N1, N11-diethylnorspermine (DENSPM) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res 9:5922–5928PubMed
128.
go back to reference Creaven PJ, Perez R, Pendyala L, Meropol NJ, Loewen G, Levine E, Berghorn E, Raghavan D (1997) Unusual central nervous system toxicity in a Phase I study of N1, N11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs 15:227–234PubMed Creaven PJ, Perez R, Pendyala L, Meropol NJ, Loewen G, Levine E, Berghorn E, Raghavan D (1997) Unusual central nervous system toxicity in a Phase I study of N1, N11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs 15:227–234PubMed
129.
go back to reference Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L (2004) Polyamine catabolism in platinum drug action: interactions between oxaliplatin and the polyamine analogue N1, N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther 3:813–822PubMed Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L (2004) Polyamine catabolism in platinum drug action: interactions between oxaliplatin and the polyamine analogue N1, N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Mol Cancer Ther 3:813–822PubMed
130.
go back to reference Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M (2005) N1, N12-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res 11:2986–2990PubMed Hiramatsu K, Takahashi K, Yamaguchi T, Matsumoto H, Miyamoto H, Tanaka S, Tanaka C, Tamamori Y, Imajo M, Kawaguchi M, Toi M, Mori T, Kawakita M (2005) N1, N12-diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Clin Cancer Res 11:2986–2990PubMed
131.
go back to reference Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, Todoroki K, Zhe Min J, Toyo’oka T (2013) High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients. Anal Chem 85:11835–11842PubMed Tsutsui H, Mochizuki T, Inoue K, Toyama T, Yoshimoto N, Endo Y, Todoroki K, Zhe Min J, Toyo’oka T (2013) High-throughput LC-MS/MS based simultaneous determination of polyamines including N-acetylated forms in human saliva and the diagnostic approach to breast cancer patients. Anal Chem 85:11835–11842PubMed
132.
go back to reference Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW (2000) Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319–38328PubMed Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J, Porter CW (2000) Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275:38319–38328PubMed
133.
go back to reference Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60PubMed Nakshatri H, Srour EF, Badve S (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr Stem Cell Res Ther 4:50–60PubMed
134.
go back to reference Dong Y, Zhu Y, Jing L, Zhou Q, Wu C, Oupický D (2012) Synthesis of bisethylnorspermine lipid prodrug as gene delivery vector targeting polyamine metabolism in breast cancer. Mol Pharm 4:1654–1664 Dong Y, Zhu Y, Jing L, Zhou Q, Wu C, Oupický D (2012) Synthesis of bisethylnorspermine lipid prodrug as gene delivery vector targeting polyamine metabolism in breast cancer. Mol Pharm 4:1654–1664
Metadata
Title
Polyamines metabolism and breast cancer: state of the art and perspectives
Authors
Manuela Cervelli
Stefano Pietropaoli
Fabrizio Signore
Roberto Amendola
Paolo Mariottini
Publication date
01-11-2014
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2014
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3156-7

Other articles of this Issue 2/2014

Breast Cancer Research and Treatment 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine